Compare AZN & ABT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AZN | ABT |
|---|---|---|
| Founded | 1992 | 1888 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 285.7B | 189.6B |
| IPO Year | N/A | 2006 |
| Metric | AZN | ABT |
|---|---|---|
| Price | $195.62 | $111.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 17 |
| Target Price | N/A | ★ $140.24 |
| AVG Volume (30 Days) | 2.1M | ★ 7.1M |
| Earning Date | 01-01-0001 | 04-23-2026 |
| Dividend Yield | 1.65% | ★ 2.30% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.72 |
| Revenue | N/A | ★ $44,328,000,000.00 |
| Revenue This Year | $10.13 | $8.92 |
| Revenue Next Year | $6.21 | $7.39 |
| P/E Ratio | $31.91 | ★ $29.57 |
| Revenue Growth | N/A | ★ 5.67 |
| 52 Week Low | $61.24 | $105.27 |
| 52 Week High | $212.71 | $137.49 |
| Indicator | AZN | ABT |
|---|---|---|
| Relative Strength Index (RSI) | 62.57 | 43.07 |
| Support Level | $89.28 | $105.27 |
| Resistance Level | $211.32 | $113.76 |
| Average True Range (ATR) | 3.21 | 1.86 |
| MACD | -5.18 | -0.06 |
| Stochastic Oscillator | 26.81 | 32.57 |
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.